Trials / Active Not Recruiting
Active Not RecruitingNCT05161325
A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
An Observational Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 525 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to assess the effectiveness and safety of Nivolumab plus Ipilimumab with or without chemotherapy as first-line treatment for participants with untreated advanced or recurrent NSCLC in the real world setting in Japan.
Conditions
Timeline
- Start date
- 2020-12-15
- Primary completion
- 2025-12-31
- Completion
- 2026-06-01
- First posted
- 2021-12-17
- Last updated
- 2025-07-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05161325. Inclusion in this directory is not an endorsement.